Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s

President Trump's stated aim to reduce GLP-1 weight loss drug prices to $150 per month, a fraction of current costs, triggered declines in Eli Lilly (-2%) and Novo Nordisk (-3%) shares, despite an administration official clarifying that negotiations are ongoing. This potential price cut, part of a broader "most-favored nation pricing" initiative, also caused Hims & Hers Health, a provider of cheaper compounded GLP-1s, to plunge over 15%, signaling significant market disruption as a $150 branded drug price would intensely compete with existing compounded options and reshape the cash market for these high-demand medications.

Analysis

President Trump's stated aim to cap GLP-1 weight loss drug prices at $150 per month, a significant reduction from current market rates, immediately impacted pharmaceutical stocks. Eli Lilly and Novo Nordisk, key players in the GLP-1 market, saw their shares decline by 2% and 3% respectively on Friday, reflecting investor concerns over potential revenue and margin compression. This proposal aligns with a broader "most-favored nation pricing" initiative to standardize U.S. drug costs with international benchmarks.

Despite a CMS administrator clarifying that negotiations are ongoing and no final agreement has been reached, the proposed $150 price point is substantially lower than the $1,300 mentioned by Trump and even the $500 discounted direct-to-consumer prices. This aggressive target would intensify competition with telehealth providers like Hims & Hers Health, which offers compounded GLP-1s for $130-$200 per month, leading to Hims & Hers' stock plunging over 15%.

The high cost of GLP-1s currently restricts market penetration, with only one in five large employers offering coverage and two-thirds reporting significant spending impact. A $150 price could dramatically expand patient access and demand, but at the expense of manufacturer profitability. The administration's continued pressure on weight loss drugmakers, following similar deals with Pfizer and AstraZeneca, signals a persistent regulatory risk to current pricing models.

Key Decisions for Investors

• Investors should closely monitor the progression of GLP-1 drug pricing negotiations, as any mandated caps could significantly alter revenue forecasts and profitability for pharmaceutical companies like Eli Lilly and Novo Nordisk.
• Evaluate the long-term competitive landscape for telehealth providers such as Hims & Hers Health, as a $150 branded GLP-1 price would erode their current cost advantage and market share.
• Consider the potential for increased volume and market expansion for GLP-1 manufacturers if lower prices drive broader adoption, weighing this against the likely severe margin compression on these high-demand medications.